Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Size, Share and Analysis by Drug Class (Alpha-1 proteinase inhibitor, Bronchodilators, Steroids, Antibiotics), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Regional Forecast, 2025-2032

The global alpha-1 antitrypsin deficiency treatment market size expected to drive significant growth by 2026. Alpha-1 antitrypsin is one of the protein synthesised in the liver and travels through the blood protecting the organs of the body from the harmful effects of other proteins. Alpha-1 Antitrypsin Deficiency (AATA), also called genetic Chronic Obstructive Pulmonary Disease (COPD), refers to a genetic condition resulting in increased susceptibility for lung and related disease.

Every individual receives two copies of alpha-1 antitrypsin genes, one form each parent. Individuals that receive one normal and one damaged or two damaged copies of alpha-1 antitrypsin genes have considered to have alpha-1 antitrypsin deficiency. The treatment of alpha-1 antitrypsin deficiency has received huge attention due to the guidelines and recommendations given by the government of different countries. In 2016, the FDA granted expanded label approval to Glassia a drug for alpha-1 antitrypsin deficiency by Kamada Ltd., for self-infusion, enabling patients to self-administer the drug. This is expected to increase the demand for Glassia further augmenting the global alpha-1 antitrypsin deficiency treatment market. 

The growth in global alpha 1 antitrypsin deficiency treatment market size is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period. 

To gain extensive insights into the market, Download for Customization

However, lack of diagnostic methods due to which alpha-1 antitrypsin deficiency remains undetected or sometimes misinterpreted as asthma is a major factor that can hamper the growth in alpha-1 antitrypsin deficiency treatment market. According to the Alpha-1 Foundation, the around 3% of all the people with Chronic Obstructive Pulmonary Disease (COPD) are likely to have undetected alpha-1 antitrypsin deficiency, which can act as a restraining factor in the growth in global alpha-1 antitrypsin deficiency treatment market. 

Key Players Covered 

Some of the major companies that are present in the global alpha 1 antitrypsin deficiency treatment market are Grifols S.A., CSL Limited, Baxter, Kamada Ltd., Takeda Pharmaceutical Company Limited, Abeona Therapeutics Inc., and other players.

SEGMENTATION

The alpha-1 proteinase inhibitor segment is estimated to witness a fast expansion which can be attributed to the new product launch, potential pipeline candidates and increased research on existing products. In August 2015, European Commission granted marketing authorization to Respreeza, a drug for the treatment of alpha-1 antitrypsin deficiency manufactured by CSL Behring in all European union, which is expected to drive the alpha-1 proteinase inhibitor segment. 

Key Insights 

• Prevalence of Alpha-1 Antitrypsin deficiency
• Pipeline analysis
• Patent snapshot
• Regulatory scenario for key countries
• Alpha-1 Antitrypsin deficiency treatment guidelines
• Key mergers and acquisitions

Regional Analysis

The global alpha-1 proteinase inhibitor market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In North America, the alpha-1 antitrypsin deficiency treatment market is expected to grow during the projected period owing to the recommendations for augmentation therapy for alpha-1 antitrypsin deficiency treatment. The Clinical Practice Guidelines published in the Journal of the COPD Foundation recommends augmentation therapy for all those who have alpha-associated lung diseases. The alpha-1 antitrypsin deficiency treatment market in Europe and Asia Pacific is anticipated to expand in the forecast period owing to the rising prevalence of alpha-1 antitrypsin deficiency. 

Key Industry Developments

• In November 2017, Grifols, S.A., received FDA approval for A1AT Genotyping Test for the diagnosis of alpha-1 antitrypsin deficiency serving as an innovative genetic test which will enable precise and early detection.
• In June 2016, the FDA granted entended label approval to Glassia a drug for alpha-1 antitrypsin deficiency by Kamada Ltd., for self-infusion, enabling patients to self-administer the drug.
• In August 2015, European Commission granted marketing authorization to Respreeza, a drug for the treatment of alpha-1 antitrypsin deficiency manufactured by CSL Behring in all European union.